Showing results (41-50 of 147) with videos related to

Sort By:
Pageof 15
Cancers|November 26, 2020
Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease ProgressionLydia Warburton, Leslie Calapre, Michelle R Pereira, et al.
Asia-Pacific Journal of Clinical Oncology|August 18, 2012
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST studyMichael Boyer, Keith Horwood, Nick Pavlakis, et al.
International Journal of Colorectal Disease|January 20, 2007
Survival rates for stage II colon cancer patients treated with or without chemotherapy in a population-based settingMelinda Morris, Cameron Platell, Kieran McCaul, et al.
Internal Medicine Journal|May 10, 2017
Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in AustraliaYeh Chen Lee, René Kroon, Bogda Koczwara, et al.
International Journal of Radiation Oncology, Biology, Physics|June 14, 2002
Measurement of lung tumor volumes using three-dimensional computer planning softwarePatrick Bowden, Richard Fisher, Michael Mac Manus, et al.
Asia-Pacific Journal of Clinical Oncology|November 15, 2018
Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanomaSagun Parakh, Manreet Randhawa, Bella Nguyen, et al.
British Journal of Cancer|November 19, 2021
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumoursJason D Lickliter, Mark Voskoboynik, Linda Mileshkin, et al.
European Journal of Cancer (Oxford, England : 1990)|August 5, 2008
Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancerAndrew Bottomley, Channa Debruyne, Enriqueta Felip, et al.
Investigational New Drugs|February 18, 2011
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxelMichael Millward, Paul Mainwaring, Alain Mita, et al.
Journal of Cancer Research and Clinical Oncology|July 27, 2022
Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patientsEmmanuel Acheampong, Michael Morici, Afaf Abed, et al.
Pageof 15